Page last updated: 2024-08-23

valrubicin and Bladder Cancer

valrubicin has been researched along with Bladder Cancer in 25 studies

Research

Studies (25)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (4.00)	18.7374
1990's	3 (12.00)	18.2507
2000's	12 (48.00)	29.6817
2010's	7 (28.00)	24.3611
2020's	2 (8.00)	2.80

Authors

Authors	Studies
Gellhaus, PT; McElree, IM; Mott, SL; Nepple, KG; O'Donnell, MA; Packiam, VT; Steinberg, RL	1
Chen, W; Hu, W; Hu, X; Huang, B; Liu, N; Wang, C; Wang, S; Xing, D; Yuan, Y; Zhu, M	1
Kamat, AM; Li, R; Spiess, PE	1
Clark, PE; Eifler, JB; Scarpato, KR	1
Sexton, WJ; Sharma, P; Zargar-Shoshtari, K	1
Dagnaes-Hansen, F; Dam, TN; de Darkó, E; Kamp, S; Rosada, C; Stenderup, K	1
Ryder, K; Slater, SJ; Smith, ND; Steinberg, GD; Strangman, NM	1
Dinney, CP; Greenberg, RE; Steinberg, GD	1
Barlow, LJ; Benson, MC	1
Hale, K; Lamm, DL; McGee, WR	1
Bahnson, RR; Bamberger, MH; Bellingham, C; Childs, SJ; Edson, M; Giantonio, B; Greenberg, RE; Israel, M; O'Dwyer, PJ; Steinberg, GD; Sweatman, T; Wood, D	1
Lamb, HM; Onrust, SV	1
Bahnson, R; Brosman, S; Middleton, R; Steinberg, G; Wajsman, Z; Wehle, M	1
Erwin-Toth, P; Grossman, HB; Lamm, DL; Magar, R; Marchetti, A; Schellhammer, PF; Wang, L	1
Baselli, EC; Greenberg, RE	1
Bahnson, R; Greenberg, RE; Gulfo, J; Israel, M; Patterson, AL; Sweatman, T; Wajsman, Z; Webber, D; Weems, L	1
Klotz, L	1
Kim, JC; Steinberg, GD	1
Hetherington, J; Kisbenedek, L; Newling, DW; Robinson, MR; Sundaram, SK	1
Luciani, LG; Murphy, WM; Neulander, E; Wajsman, Z	1
Alsikafi, NF; Kuznetsov, DD; O'Connor, RC; Steinberg, GD	1
Randall, S	1
Haisfield-Wolfe, ME	1
Herrod, HG; Hunter, RF; Israel, M; Niell, HB	1

Reviews

10 review(s) available for valrubicin and Bladder Cancer

Article	Year
ALT-803 in the treatment of non-muscle-invasive bladder cancer: Preclinical and clinical evidence and translational potential. Frontiers in immunology, 2022, Volume: 13 Topics: BCG Vaccine; CD8-Positive T-Lymphocytes; Humans; Mycobacterium bovis; Neoplasm Recurrence, Local; United States; Urinary Bladder Neoplasms	2022
Management of noninvasive bladder cancers. Current opinion in oncology, 2015, Volume: 27, Issue:3 Topics: Administration, Intravesical; Antineoplastic Agents; Cystectomy; Doxorubicin; Early Detection of Cancer; Humans; Neoplasm Recurrence, Local; Risk Assessment; Risk Reduction Behavior; United States; Urinary Bladder Neoplasms	2015
Valrubicin in refractory non-muscle invasive bladder cancer. Expert review of anticancer therapy, 2015, Volume: 15, Issue:12 Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Disease Progression; Disease-Free Survival; Doxorubicin; Humans; Urinary Bladder Neoplasms	2015
Experience with newer intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer. Current urology reports, 2013, Volume: 14, Issue:2 Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Humans; Mitomycin; Paclitaxel; Taxoids; Thiotepa; Treatment Failure; Urinary Bladder Neoplasms	2013
Bladder cancer: current optimal intravesical treatment. Urologic nursing, 2005, Volume: 25, Issue:5 Topics: Adjuvants, Immunologic; Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Cystectomy; Doxorubicin; Drug Administration Schedule; Epirubicin; Humans; Interferon-alpha; Mitomycin; Neoplasm Recurrence, Local; Nurse's Role; Patient Selection; Risk Factors; Salvage Therapy; Survival Rate; Thiotepa; Treatment Failure; United States; Urinary Bladder Neoplasms	2005
Valrubicin. Drugs & aging, 1999, Volume: 15, Issue:1 Topics: Administration, Intravesical; Animals; Carcinoma in Situ; Clinical Trials as Topic; Dose-Response Relationship, Drug; Doxorubicin; Humans; Lethal Dose 50; Urinary Bladder Neoplasms	1999
Intravesical therapy for superficial bladder cancer. Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:5 Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Anticarcinogenic Agents; Antineoplastic Agents; Carcinoma, Transitional Cell; Doxorubicin; Epirubicin; Humans; Interferons; Mitomycin; Mycobacterium bovis; Neoplasm, Residual; Photochemotherapy; Photosensitizing Agents; Thiotepa; Urinary Bladder Neoplasms	2000
Medical management of patients with refractory carcinoma in situ of the bladder. Drugs & aging, 2001, Volume: 18, Issue:5 Topics: Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Doxorubicin; Humans; Immunotherapy; Photochemotherapy; Urinary Bladder Neoplasms	2001
Intravesical valrubicin in the treatment of carcinoma in situ of the bladder. Expert opinion on pharmacotherapy, 2001, Volume: 2, Issue:6 Topics: Administration, Intravesical; Antineoplastic Agents; Carcinoma in Situ; Carcinoma, Transitional Cell; Clinical Trials as Topic; Doxorubicin; Guidelines as Topic; Humans; Molecular Structure; Urinary Bladder Neoplasms	2001
Valrubicin: an alternative to radical cystectomy for carcinoma in situ of the bladder. Urologic nursing, 2001, Volume: 21, Issue:1 Topics: Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Cystectomy; Doxorubicin; Humans; Neoplasm Staging; Nursing Assessment; Urinary Bladder Neoplasms	2001

Trials

5 trial(s) available for valrubicin and Bladder Cancer

Article	Year
Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder. Urology, 1997, Volume: 49, Issue:3 Topics: Administration, Intravesical; Aged; Aged, 80 and over; Anthracyclines; Carcinoma, Transitional Cell; Doxorubicin; Female; Humans; Male; Middle Aged; Urinary Bladder Neoplasms	1997
Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. The Journal of urology, 2000, Volume: 163, Issue:3 Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; BCG Vaccine; Carcinoma in Situ; Doxorubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Treatment Failure; Urinary Bladder Neoplasms	2000
Management of patients with Bacilli Calmette-Guérin-refractory carcinoma in situ of the urinary bladder: cost implications of a clinical trial for valrubicin. Clinical therapeutics, 2000, Volume: 22, Issue:4 Topics: BCG Vaccine; Carcinoma in Situ; Costs and Cost Analysis; Cystectomy; Doxorubicin; Humans; Injections; Models, Economic; Urinary Bladder; Urinary Bladder Neoplasms	2000
Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer. Urology, 2000, Aug-01, Volume: 56, Issue:2 Topics: Administration, Intravesical; Aged; Carcinoma in Situ; Combined Modality Therapy; Doxorubicin; Drug Administration Schedule; Humans; Male; Pilot Projects; Postoperative Complications; Salvage Therapy; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms; Urination Disorders	2000
The use of valrubicin for the chemoresection of superficial bladder cancer -- a marker lesion study. European urology, 2001, Volume: 39, Issue:6 Topics: Administration, Intravesical; Aged; Carcinoma, Transitional Cell; Doxorubicin; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Time Factors; Urinary Bladder; Urinary Bladder Neoplasms	2001

Other Studies

10 other study(ies) available for valrubicin and Bladder Cancer

Article	Year
Sequential Intravesical Valrubicin and Docetaxel for the Salvage Treatment of Non-Muscle-Invasive Bladder Cancer. The Journal of urology, 2022, Volume: 208, Issue:5 Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Docetaxel; Doxorubicin; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Urinary Bladder Neoplasms	2022
Treatment Options for Patients with Recurrent Tumors After BCG Therapy: Are We Ignoring the Obvious? European urology, 2018, Volume: 74, Issue:4 Topics: Adjuvants, Immunologic; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Clinical Trials as Topic; Cystectomy; Doxorubicin; Humans; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Patient Selection; Practice Guidelines as Topic; Urinary Bladder Neoplasms	2018
Valrubicin in a topical formulation treats psoriasis in a xenograft transplantation model. The Journal of investigative dermatology, 2010, Volume: 130, Issue:2 Topics: Administration, Topical; Adult; Aged; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Epidermis; Humans; Keratinocytes; Mice; Mice, SCID; Middle Aged; Neoplasm Transplantation; Psoriasis; Urinary Bladder Neoplasms	2010
Factors affecting valrubicin response in patients with bacillus Calmette-Guérin-refractory bladder carcinoma in situ. Postgraduate medicine, 2011, Volume: 123, Issue:3 Topics: Aged; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Clinical Trials, Phase III as Topic; Doxorubicin; Female; Humans; Male; Middle Aged; Time Factors; Urinary Bladder Neoplasms	2011
Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin. Urologic oncology, 2013, Volume: 31, Issue:8 Topics: Abdominal Pain; Administration, Intravesical; Adult; Aged; Aged, 80 and over; BCG Vaccine; Carcinoma in Situ; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Contraindications; Doxorubicin; Dysuria; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Outcome Assessment, Health Care; Randomized Controlled Trials as Topic; Treatment Failure; Urinary Bladder Neoplasms; Urinary Tract Infections	2013
Valrubicin for bladder cancer. The Medical letter on drugs and therapeutics, 1999, Mar-26, Volume: 41, Issue:1049 Topics: Carcinoma in Situ; Clinical Trials as Topic; Doxorubicin; Humans; Urinary Bladder Neoplasms	1999
Re: Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Journal of urology, 2000, Volume: 164, Issue:5 Topics: Adjuvants, Immunologic; BCG Vaccine; Carcinoma in Situ; Cystectomy; Doxorubicin; Humans; Urinary Bladder Neoplasms	2000
Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach. Urology, 2001, Volume: 58, Issue:3 Topics: Administration, Intravesical; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma, Transitional Cell; Cystectomy; Cystoscopy; Doxorubicin; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Secondary Prevention; Treatment Outcome; Urinary Bladder Neoplasms	2001
Drug handling questioned. Urologic nursing, 2001, Volume: 21, Issue:3 Topics: Antineoplastic Agents; Carcinoma in Situ; Doxorubicin; Humans; Medical Waste Disposal; Urinary Bladder Neoplasms	2001
Effects of N-trifluoroacetyladriamycin-14-valerate (AD-32) on human bladder tumor cell lines. Cancer chemotherapy and pharmacology, 1987, Volume: 19, Issue:1 Topics: Biological Transport; Cell Line; Doxorubicin; Drug Evaluation, Preclinical; Drug Resistance; Drug Synergism; Hematopoietic Stem Cells; Humans; Temperature; Tumor Stem Cell Assay; Urinary Bladder Neoplasms; Verapamil	1987